Search

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

How to apply for the EHA Mentorship Program

EHA Portal accountTo apply, either as a mentor or a mentee, you must be registered on the EHA Portal (Fluxx).

Read more

The invisible burden of the pandemic

Writing about my perspective on the COVID-19 pandemic has been on my mind for some time.

Read more

Meet YoungEHA leaders Verena and Heiko

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee.

Read more

Standards for functional precision medicine project update, December 2023

A project update from Prof Philipp Staber. We're confident that we'll successfully finish our SWG-initiated small research project, ‘standards for functional precision medicine (StFPM),’ within the next six months.

Read more

A journey to hematology – a dream come true

YoungEHA proudly presents our first blog authored by a guest writer, Dr. Ana Zelić Kerep, a resident physician in the Department of Hematology, University Hospital Center Zagreb, Croatia. A journey to hematology – a dream come true

by Dr.

Read more

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more